Growth Metrics

Halozyme Therapeutics (HALO) Amortization - Intangibles (2022 - 2025)

Historic Amortization - Intangibles for Halozyme Therapeutics (HALO) over the last 4 years, with Q3 2025 value amounting to $17.8 million.

  • Halozyme Therapeutics' Amortization - Intangibles changed 0.0% to $17.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $71.0 million, marking a year-over-year change of 0.14%. This contributed to the annual value of $71.0 million for FY2024, which is 369.24% down from last year.
  • Halozyme Therapeutics' Amortization - Intangibles amounted to $17.8 million in Q3 2025, which was down 0.0% from $17.8 million recorded in Q2 2025.
  • Halozyme Therapeutics' Amortization - Intangibles' 5-year high stood at $27.2 million during Q3 2022, with a 5-year trough of $4.6 million in Q4 2022.
  • For the 4-year period, Halozyme Therapeutics' Amortization - Intangibles averaged around $17.2 million, with its median value being $17.8 million (2023).
  • Over the last 5 years, Halozyme Therapeutics' Amortization - Intangibles had its largest YoY gain of 29020.21% in 2023, and its largest YoY loss of 2519.77% in 2023.
  • Over the past 4 years, Halozyme Therapeutics' Amortization - Intangibles (Quarter) stood at $4.6 million in 2022, then soared by 290.2% to $17.8 million in 2023, then changed by 0.0% to $17.8 million in 2024, then changed by 0.0% to $17.8 million in 2025.
  • Its Amortization - Intangibles stands at $17.8 million for Q3 2025, versus $17.8 million for Q2 2025 and $17.8 million for Q1 2025.